NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Kidney and renal pelvis
Kidney and renal pelvis · 80,450 new · 15,160 deaths (ACS 2026) · mortality 3.4 per 100k · 5-yr RS 79.2% (SEER)
Mortality 3.4 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 1.8% (SEER Stat Facts). 687,999 people living with kidney and renal pelvis cancer in 2023. No encoded screening interval. Not a VHL formula.
687,999 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 65 · at death 73 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 24.4 / women 12.3 per 100k · mortality men 5.0 / women 2.1 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases rising 0.7% each year (2014–2023). Death-rate trend is not restated here. Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval. One official Joinpoint percent collides with a locked artboard figure, so that side is not restated.
Highest new-case rate: Non-Hispanic American Indian/Alaska Native men 37.4 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native men 9.2 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 25.5 | 14.9 | 4.7 | 2.0 |
| Non-Hispanic American Indian/Alaska Native | 37.4 | 20.0 | 9.2 | 3.8 |
| Non-Hispanic Asian/Pacific Islander | 12.7 | 5.9 | 2.4 | 1.0 |
| Non-Hispanic Black | 26.8 | 13.3 | 4.9 | 2.1 |
| Non-Hispanic White | 25.1 | 12.0 | 5.3 | 2.2 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
No USPSTF population-screening recommendation is cited for this stub.
ACS / SEER pin only. Not encoded. Not a screening recommendation.
ACS early-detection pointer
ACS 2024 · People at average risk of kidney cancer · ACS (2024): there are no recommended screening tests for kidney cancer for people at average risk. Urinalysis, CT, MRI, and ultrasound are named as tests that can find some kidney cancers, but none is recommended as an average-risk screen. Inherited conditions and long-term dialysis are named as increased-risk contexts; those imaging calendars are not encoded. Not a urinalysis or VHL engine.
Cited ACS statement only. Not a screening engine. ACS-kidney-detect
Surveillance pointer
ACS-kidney-follow 2024 · cited only · ACS living-as-a-survivor page names follow-up visits that may include imaging and blood tests, with cadence depending on stage and treatment. Those months are not encoded. Not an imaging surveillance engine.
Named public source only. Not a personal follow-up calendar. ACS-kidney-follow
Surveillance pointer
ACS-kidney-follow 2024 · cited only · ACS living-as-a-survivor page names second cancers after kidney-cancer treatment, including a second kidney cancer. Named later-cancer sites are not encoded. Complementary to the living-as pointer. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-kidney-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen treatment, plus urinary retention, leakage, or UTIs. Those names are not encoded. Complementary to the living-as pointer. Not a urinalysis or VHL engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page, developed with ASCO review, names a cancer treatment summary and a survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical, breast, colorectal, or lung screening may be named. Those plans and screens are not encoded. Complementary to the living-as and late-effects pointers. Not a urinalysis or VHL engine. No invented printout field.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACS-kidney-follow 2024 · empty on purpose · ACS living-as-a-survivor page names treatment side effects that may last or appear later. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-kidney-follow
Toxicity pointer
ACS-kidney-follow 2024 · empty on purpose · ACS living-as-a-survivor page names later cancers after kidney-cancer treatment. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-kidney-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions and urinary retention after abdomen treatment. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after kidney treatment. Those late-effect tests are not encoded. Complementary to the living-as pointer. No invented printout field. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
Kidney, thyroid, and leukemia stay unmapped. Cadences are not encoded.
All printouts →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-stub-kidney · stub · none · v2-stub-kidney
SEER 5-year relative survival by stage (cited stub)
Localized 93.6% · Regional 77.6% · Distant 20.3% · All 79.2%
Kidney and renal pelvis. SEER Cancer Stat Facts.
Percent of cases by stage (SEER Stat Facts)
Localized 66% · Regional 17% · Distant 15% · Unknown 3%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Kidney and renal pelvis.
lifetime
Kidney and renal pelvis birth-to-death
≈ 1.8%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no recommended average-risk kidney screen
Cited ACS 2024 statement only. Not a urinalysis, CT, or VHL imaging engine.
not encoded
surveillance
ACS follow-up cited — kidney months not encoded
Cited ACS living-as-a-survivor page only. Not an imaging surveillance engine.
not encoded
toxicity
ACS late effects cited — kidney months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Noah · Plan — skin cancer
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no recommended average-risk kidney screen
Cited ACS 2024 statement only. Not a urinalysis, CT, or VHL imaging engine.
not encoded
surveillance
ACS follow-up cited — kidney months not encoded
Cited ACS living-as-a-survivor page only. Not an imaging surveillance engine.
not encoded
toxicity
ACS late effects cited — kidney months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Walter · S1 prostate
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no recommended average-risk kidney screen
Cited ACS 2024 statement only. Not a urinalysis, CT, or VHL imaging engine.
not encoded
surveillance
ACS follow-up cited — kidney months not encoded
Cited ACS living-as-a-survivor page only. Not an imaging surveillance engine.
not encoded
toxicity
ACS late effects cited — kidney months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Priya · average-risk
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no recommended average-risk kidney screen
Cited ACS 2024 statement only. Not a urinalysis, CT, or VHL imaging engine.
not encoded
surveillance
ACS follow-up cited — kidney months not encoded
Cited ACS living-as-a-survivor page only. Not an imaging surveillance engine.
not encoded
toxicity
ACS late effects cited — kidney months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.